-
Home
-
Media and Information
- Press Releases
Press Releases
- Details
ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) attended a U.S. Food and Drug Administration (FDA)–sponsored workshop to address growing concerns regarding drug shortages in certain sectors of the pharmaceutical industry September 26.
- Details
This month, Florida and California are recognizing "Plasma Protein Therapies Month," by raising awareness for the valuable contributions of plasma donors and for the rare, genetic diseases treated with the therapies that are made possible through plasma donation.
- Details
BRUSSELS, BELGIUM - The Plasma Protein Therapeutics Association (PPTA) welcomes the findings of the ConQuaestor report on the financing of Sanquin, the Dutch National Fractionator.
- Details
ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) believes the Internal Revenue Services' issuance of temporary and proposed regulations implementing the annual pharmaceutical fee undermines patients with rare diseases and fails to take into account concerns expressed by leading consumer organizations and Congress.
- Details
ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) recommends that the Centers for Medicare and Medicaid Services (CMS) take necessary steps to improve drug reimbursement under the Hospital Outpatient Perspective Payment System (OPPS).
- Details
ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) applauds the introduction of bipartisan legislation, the Preserving Access to Orphan Drugs Act (H.R. 2672) and (S. 1423), which will safeguard the development of drugs and therapies that treat patients with rare diseases by eliminating barriers to innovation.
- Details
ANNAPOLIS, MD - PPTA opposes New Jersey Assembly Bill 2003 passed by the New Jersey Assembly Appropriations Committee on June 13 that imposes a new tax on therapies used to treat bleeding disorders like hemophilia.
- Details
The U.S. Department of Health and Human Services (HHS) has appointed Plasma Protein Therapeutics Association (PPTA) industry expert Mary Gustafson to serve for a two-year term on its Advisory Committee on Blood Safety and Availability (ACBSA).
- Details
BRUSSELS, BELGIUM - The Plasma Protein Therapeutics Association (PPTA) hosted a discussion forum at the Dutch Parliament in The Hague yesterday. The forum was attended by representatives of the Dutch Ministry of Health, Members of the Dutch Parliament, the patient community and the national manufacturer of plasma protein therapies: Sanquin.
- Details
ANNAPOLIS, MD - The Plasma Protein Therapeutics Association commends the Florida legislature for allowing Medicaid recipients to continue to receive their clotting factor and the overlay services through the agency's hemophilia disease management program, rather than forcing them to switch to a managed care plan for their therapeutic needs.
Media and Information
PPTA News
-
PPTA Statement on “How Blood-Plasma Companies Target the Poorest Americans” +
The article, “How Blood-Plasma Companies Target the Poorest Americans,” by H. Luke Shaefer and Analidis Ochoa, published in The Atlantic on March 15, was unfair to plasma donors as well as to individuals living with rare, genetic, and chronic diseases who rely on access to plasma protein therapies. Plasma donors are due our gratitude and respect, not sweeping negative characterizations.
Read More -
Highlights from the 2018 IPPC +
Mr. Jan M. Bult, President & CEO, PPTA, opened the well-attended IPPC 2018 by welcoming the more than 300 attendees to Budapest. PPTA thanks its sponsors who help make the IPPC possible every year. Download the IPPC app (available in the Apple AppStore and Android Market/Google Play) for Apple or Android devices) for a complete list of sessions and many of the presentations.
Read More -
GLOBAL INITIATIVE DRAWS ATTENTION TO RARE DISEASE TREATMENTS +
“How Is Your Day?” highlights value of plasma protein therapies in improving patients’ lives
Budapest, HUNGARY (March 13)– The Plasma Protein Therapeutics Association (PPTA) today unveiled its new global initiative, “How Is Your Day?” –Making the difference with plasma proteins, in conjunction with the annual International Plasma Protein Congress. “How Is Your Day?” will focus on differentiating these unique therapies from traditional pharmaceuticals and building awareness of the value they provide for people living with rare, life-threatening, chronic, and genetic diseases.
Read More
- 1
- 2
- 3
The Source, the international magazine of the plasma protein therapeutics industry, is published quarterly.
Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.